What You Should Know:
- Reimagine Care, the nation’s leading provider of on-demand cancer care, today announced a pilot collaboration with MedStar Health, the largest healthcare provider in Maryland and the Washington, D.C., region.
- MedStar Health will integrate Reimagine Care’s innovative on-demand oncology care platform into its cancer care delivery model, offering patients a seamless extension from their in-clinic care plan into the home.
Extending High-Quality Cancer Care
Read More
Oncology Platform
Flatiron Health, NRG Oncology to Streamline Cancer Clinical Trials with EHR-to-EDC
What You Should Know:
- Flatiron Health, a healthtech company focused on revolutionizing clinical research through technology integration, has announced a collaboration with NRG Oncology, a clinical research consortium within the National Cancer Institute's (NCI) National Clinical Trials Network (NCTN).
- The partnership aims to deploy Flatiron’s Clinical Pipe™ in a multicenter NRG clinical trial, streamlining data entry and accelerating study timelines.
Supporting
Read More
Oatmeal Health Unveils AI Diagnostic Platform for Lung Cancer Screening in Underserved FQHC Communities
What You Should Know:
- Oatmeal Health, an innovator in AI-driven cancer screening launches its AI-powered radiology risk stratification platform for lung cancer.
- The solution provides a fully reimbursable second-opinion diagnostic tool covered by Medicare, making it more accessible and affordable for healthcare providers and patients.
AI-Powered Lung Nodule Analysis
Lung cancer remains a leading cause of cancer-related deaths worldwide, but screening rates remain
Read More
C the Signs Raises $8M to Expand AI-Powered Cancer Detection to the U.S.
What You Should Know:
- C the Signs, a developer of AI-powered cancer detection solutions, today announced an $8 million funding round led by Khosla Ventures.
- The investment will fuel the company's expansion from the United Kingdom, where it has already achieved significant success in early cancer detection, to the United States.
Cancer Screening and Improve Patient Outcomes
C the Signs addresses a critical gap in cancer care by identifying patients at risk of cancer at
Read More
PreciseDx Raises $20.7M for AI-Powered Cancer Risk Assessments
What You Should Know:
- PreciseDx, a pioneering company in oncology diagnostics utilizing artificial intelligence (AI) raises $20.7M in Series B funding led by Eventide Asset Management with participation from Labcorp, Quest Diagnostics, GenHenn Capital Venture, and existing investors. This brings the company's total funding to date to $31.5M.
- The new funding will enable PreciseDx to accelerate its growth and expand its operations. The company plans to invest in talent
Read More
Thyme Care Secures $95M to Expand Value-Based Cancer Care Platform
What You Should Know:
- Thyme Care, a leading value-based cancer care enabler raises $95M in funding capital led by Concord Health Partners, with participation from existing investors including CVS Health® Ventures, Town Hall Ventures, a16z Bio + Health, AlleyCorp, Echo Health Ventures, Foresite Capital, and new investor SignalFire. The funding brings Thyme Care's total funding to $178M.
- Thyme Care is a value-based cancer care enabler focused on improving patient outcomes and
Read More
Pangea Biomed’s ENLIGHT-DP Predicts Cancer Treatment Response from Simple Scans
What You Should Know:
- Pangea Biomed, a leader in precision oncology, announced a significant breakthrough in its ENLIGHT cancer response predictor. A new study published in Nature Cancer demonstrates the effectiveness of their ENLIGHT-DP platform, revealing its ability to predict cancer treatment response across various types and drugs using only routine pathology slides.
- While these findings are promising, further validation and testing are planned for regulatory
Read More
COTA and FDA Extend Collaboration to Advance Use of Real-World Data in Cancer Research
What You Should Know:
- COTA, a leader in real-world data and analytics solutions, today announced a five-year extension of its research collaboration with the U.S. Food and Drug Administration's (FDA) Oncology Center of Excellence (OCE).
- The five-year extension builds upon a successful partnership established in 2018 and signifies a continued commitment to utilizing real-world data (RWD) to enhance cancer treatment and regulatory decisions.
Building on a Successful
Read More
Guardant Health, Flatiron Health Integrate Genomic Profiling Tests into OncoEMR® Platform
Ibex Medical Analytics Raises $55M to Drive AI for Cancer Diagnosis Adoption Globally
What You Should Know:
– Ibex Medical Analytics (Ibex), a provider of AI-powered cancer diagnostics raises $55M in Series C financing round led by 83North.
- The round also included participation from Sienna Venture Capital and existing investors in the company, Octopus Ventures, aMoon, Planven Entrepreneur Ventures and Dell Technologies Capital. The financing brings total funding to over $100M since Ibex’s inception in 2016.
Read More
